Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Udo Oppermann, Director of Laboratory Sciences at NDORMS, is the Scientific Director for Oxford in a new alliance between the University of Oxford and Bayer Healthcare. This strategic research alliance in the area of gynaecological therapies is for an initial period of two years, but is open for extension to up to five years.

Professor Udo Oppermann, Director of Laboratory Sciences at NDORMS, is the Scientific Director for Oxford in a new alliance between the University of Oxford and Bayer Healthcare.

This strategic research alliance in the area of gynaecological therapies is for an initial period of two years, but is open for extension to up to five years. The multi-target collaboration will focus on endometriosis and uterine fibroids with the goal of discovering and developing innovative treatment options for these diseases, which affect millions of women worldwide and are still poorly understood.

Professor Oppermann said: "Clearly novel approaches are required to better understand these devastating diseases and develop novel therapeutic concepts to treat endometriosis and uterine fibroids. Oxford, with its excellent translational approaches and departments can perfectly contribute to this challenging task."

Professor Andrew Hamilton, Vice Chancellor of the University of Oxford commented: "This collaboration draws on the particular skill sets of each partner in the development of innovative new therapies that could benefit millions of women around the world, and shows Oxford's commitment to work jointly with industry to develop novel medicines".

Research projects will be jointly performed at the Bayer HealthCare RD Centre in Berlin, Germany, and at several University of Oxford centres and institutes participating in the alliance.

Target discovery and pre-clinical validation will be performed by the Target Discovery Institute under the lead of Professor Stefan Knapp together with the Botnar - Kennedy Tissue platform located at the Botnar Research Centre. Clinical expertise will be provided by the Oxford Endometriosis CaRe Centre, a collaboration between the Oxford University Hospitals NHS Trust and the Nuffield Department of Obstetrics and Gynaecology, which is one of the leading centres in the world for clinical care and research in endometriosis.

Bayer HealthCare is the world leader in the field of hormonal contraception and a pioneer in women's healthcare focusing on innovations in contraception and gynaecological therapies.

"This new partnership with one of the world's leading institutions brings together the drug development expertise at Bayer with the disease and target expert knowledge at the University of Oxford," said Professor Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. "The collaboration provides us with the opportunity to jointly develop novel treatment options for women suffering from these debilitating diseases"

Under the terms of the agreement both parties will contribute innovative drug targets and high quality technology infrastructures. Furthermore, Bayer HealthCare and the University of Oxford will share responsibilities from basic research to early clinical trials in these two diseases.

For the full article, see University of Oxford and Bayer HealthCare join forces to develop innovative gynaecological treatments on the Medical Sciences Division website.

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).